News
Language
Deals
Literature
CD DVD Blu ray
Ulm
local news
Live Cam
Radio
map
Fun
Tetris
Super Mario
Triviador
Checkers
2048
Dog Simulator
Sudoku
Mahjong
Trips
Medicine
EKM
GTE
Anatomy
Mathematics
CAS
Calculator
Physics
Astrophysics
Contact
Imprint
Ulm
English
en
Français
fr
Deutsch
de
News
Language
Deals
Literature
CD DVD Blu ray
Ulm
local news
Live Cam
Radio
map
Fun
Tetris
Super Mario
Triviador
Checkers
2048
Dog Simulator
Sudoku
Mahjong
Trips
Medicine
EKM
GTE
Anatomy
Mathematics
CAS
Calculator
Physics
Astrophysics
Contact
Imprint
English
en
Français
fr
Deutsch
de
EKM WS18 Introduction to Clinical Medicine
GTE Historical development of medicine
Medicine
Button
Robert Koch Institute
Red List
Pub Med
Dolosys
Cardiology
MAY
07
Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention?
By:
Simone Fezzi
on
MAY
07
Nature Reviews Cardiology, Published online: 07 May 2024; doi:10.1038/s41569-024-01014-0In 1993, Lincoff and Topol claimed that the thrombolytic treatment of ST-segment elevation myocardial infarction was suboptimal in many patients and gave an ‘illusion of reperfusion’. In this Perspective article, the authors propose that a similar illusion of revascularization exists for contemporary percutaneous revascularization in patients with coronary artery disease and ischaemia, and identify how outcomes might be improved.
Read more >>
MAY
03
No benefit of apoA-I infusion after myocardial infarction
By:
Gregory B. Lim
on
MAY
03
Nature Reviews Cardiology, Published online: 03 May 2024; doi:10.1038/s41569-024-01031-zIn the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.
Read more >>
MAY
02
Screening for
Helicobacter pylori
infection in patients with cardiovascular and gastrointestinal disease
By:
Jonatan Wärme
on
MAY
02
Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01028-8Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease
Read more >>
MAY
02
Reply to ‘Screening for
Helicobacter pylori
infection in patients with cardiovascular and gastrointestinal disease’
By:
Azita H. Talasaz
on
MAY
02
Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01029-7Reply to ‘Screening for Helicobacter pylori infection in patients with cardiovascular and gastrointestinal disease’
Read more >>
MAY
02
Stress and cardiovascular disease: an update
By:
Viola Vaccarino
on
MAY
02
Nature Reviews Cardiology, Published online: 02 May 2024; doi:10.1038/s41569-024-01024-yPhysiological responses to stress are thought to increase the risk of cardiovascular disease via haemodynamic, vascular and immune perturbations. In this Review, Vaccarino and Bremner focus on issues with the measurement of psychological stress and the underlying pathobiology connecting stress to the risk of cardiovascular disease.
Read more >>
APR
25
Periodontal treatment reduces AF recurrence
By:
Gregory B. Lim
on
APR
25
Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01036-8Treatment for periodontal disease might reduce the recurrence of atrial fibrillation (AF) in patients undergoing ablation, suggesting that periodontitis is a modifiable risk factor for AF.
Read more >>
APR
25
The coronary sinus reducer improves angina symptoms in patients with stable CAD
By:
Karina Huynh
on
APR
25
Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01033-xFindings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural myocardial perfusion.
Read more >>
APR
25
Targeting immune cell recruitment in atherosclerosis
By:
Yvonne Döring
on
APR
25
Nature Reviews Cardiology, Published online: 25 April 2024; doi:10.1038/s41569-024-01023-zIn this Review, the authors discuss the receptors, ligands and interactors that regulate immune cell recruitment in atherosclerosis, describe mechanisms that promote the resolution of inflammation in atherosclerotic lesions, and highlight potential strategies to target these pathways for the treatment of atherosclerotic cardiovascular disease.
Read more >>
Weitere Beiträge
Clinical Oncology
MAY
07
CAR T cells in multiple myeloma: lessons learned
By:
Vinay Prasad
on
MAY
07
Nature Reviews Clinical Oncology, Published online: 07 May 2024; doi:10.1038/s41571-024-00898-8The question of whether chimeric antigen receptor (CAR) T cell therapies should be used in earlier lines (after 1–2 prior lines of therapy) in patients with relapsed and/or refractory multiple myeloma remains unanswered. Herein, I argue that the use of surrogate end points that lack a robust correlation with overall survival, as well as suboptimal control arms and use of post-progression therapies, limit the ability to make definitive conclusions on the basis of the available data.
Read more >>
MAY
01
NIR-II light in clinical oncology: opportunities and challenges
By:
Zeyu Zhang
on
MAY
01
Nature Reviews Clinical Oncology, Published online: 01 May 2024; doi:10.1038/s41571-024-00892-0Expansion of the utilizable spectrum of light from the visible region to the near-infrared (NIR) window has greatly facilitated the clinical application of optical technologies for cancer imaging and phototherapy. However, use of light in the first NIR region (NIR-I) has important limitations, some of which might be overcome with emerging technologies utilizing NIR-II light. In this Review, the authors describe the current clinical experience with NIR-II-based cancer imaging and phototherapy, and discuss emerging NIR-II-based approaches that might further enhance patient outcomes. They also highlight challenges that will need to be addressed to translate NIR-II-based modalities from bench to bedside.
Read more >>
APR
29
Laparoscopic hemihepatectomy is safe and effective
By:
Peter Sidaway
on
APR
29
Nature Reviews Clinical Oncology, Published online: 29 April 2024; doi:10.1038/s41571-024-00900-3Laparoscopic hemihepatectomy is safe and effective
Read more >>
APR
29
Adjuvant pembrolizumab improves overall survival in patients with RCC
By:
Peter Sidaway
on
APR
29
Nature Reviews Clinical Oncology, Published online: 29 April 2024; doi:10.1038/s41571-024-00901-2Adjuvant pembrolizumab improves overall survival in patients with RCC
Read more >>
APR
25
From AACR 2024
By:
Diana Romero
on
APR
25
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00897-9From AACR 2024
Read more >>
APR
25
Adjuvant alectinib improves outcomes in
ALK
-mutant NSCLC
By:
Diana Romero
on
APR
25
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00899-7Adjuvant alectinib improves outcomes in ALK-mutant NSCLC
Read more >>
APR
25
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype?
By:
Christopher Nevala-Plagemann
on
APR
25
Nature Reviews Clinical Oncology, Published online: 25 April 2024; doi:10.1038/s41571-024-00896-wThe FDA has approved nanoliposomal irinotecan, 5-fluorouracil, leucovorin and oxaliplatin (NALIRIFOX) for patients with metastatic pancreatic adenocarcinoma on the basis of results from the NAPOLI 3 trial, in which this four-drug regimen improved overall survival relative to a doublet regimen. Here we discuss how, in the context of prior results from the PRODIGE 4 trial testing 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (modified FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and health-care systems to financial toxicities.
Read more >>
APR
22
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials
By:
Ghulam Rehman Mohyuddin
on
APR
22
Nature Reviews Clinical Oncology, Published online: 22 April 2024; doi:10.1038/s41571-024-00895-xCertain subsets of patients with multiple myeloma or its precursor conditions are overtreated with current approaches to therapy. Herein, we highlight several key areas where we believe de-escalation of treatment is needed. Dedicated trials to assess these de-escalation approaches and urgent changes to current clinical practices are needed.
Read more >>
Weitere Beiträge
Endocrinology
MAY
08
Publisher Correction: Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency
By:
Cihan Atila
on
MAY
08
Nature Reviews Endocrinology, Published online: 08 May 2024; doi:10.1038/s41574-024-00998-6Publisher Correction: Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency
Read more >>
MAY
07
Author Correction: Targeting the incretin system in obesity and type 2 diabetes mellitus
By:
Saleem Ansari
on
MAY
07
Nature Reviews Endocrinology, Published online: 07 May 2024; doi:10.1038/s41574-024-00997-7Author Correction: Targeting the incretin system in obesity and type 2 diabetes mellitus
Read more >>
MAY
01
A congress on head and neck paragangliomas: advancing clinical care
By:
Mario Sanna
on
MAY
01
Nature Reviews Endocrinology, Published online: 01 May 2024; doi:10.1038/s41574-024-00987-9The First International Congress on Head and Neck Paragangliomas in 2023 launched a global initiative directed towards improving the management of head and neck paragangliomas (HNPGLs), including prevention, treatment and research. The Congress highlighted a lack of international evidence-based consensuses and guidelines for HNPGLs. The Congress will now convene triennially to foster personalized medicine and research to advance patient care.
Read more >>
MAY
01
Thyroid function and iodine intake: global recommendations and relevant dietary trends
By:
Sarah C. Bath
on
MAY
01
Nature Reviews Endocrinology, Published online: 01 May 2024; doi:10.1038/s41574-024-00983-zThis Review discusses the importance of adequate iodine intake for thyroid function, outlining the varying global intake recommendations. Iodine is also considered in the context of the increasing prevalence of overweight and obesity, as well as dietary trends such as cardioprotective salt restriction and plant-based diets.
Read more >>
MAY
01
Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency
By:
Cihan Atila
on
MAY
01
Nature Reviews Endocrinology, Published online: 01 May 2024; doi:10.1038/s41574-024-00985-xCentral diabetes insipidus has been renamed as arginine vasopressin deficiency. This Review discusses advances in diagnosis and management of arginine vasopressin deficiency. In addition, the possibility of oxytocin deficiency in these patients is considered, as well as oxytocin provocation testing and the future therapeutic potential of oxytocin replacement.
Read more >>
APR
29
Optimizing the treatment of hypothyroidism
By:
Antonio C. Bianco
on
APR
29
Nature Reviews Endocrinology, Published online: 29 April 2024; doi:10.1038/s41574-024-00989-7Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.
Read more >>
APR
24
New genes associated with adult-onset obesity
By:
Claire Greenhill
on
APR
24
Nature Reviews Endocrinology, Published online: 24 April 2024; doi:10.1038/s41574-024-00991-zNew genes associated with adult-onset obesity
Read more >>
APR
22
Mild autonomous cortisol secretion: pathophysiology, comorbidities and management approaches
By:
Alessandro Prete
on
APR
22
Nature Reviews Endocrinology, Published online: 22 April 2024; doi:10.1038/s41574-024-00984-yMild autonomous cortisol secretion from benign adrenocortical adenomas (usually diagnosed incidentally) is associated with cardiometabolic risk and other comorbidities, but without the signs of overt Cushing syndrome. This Review outlines the mechanisms, complications and comorbidities, diagnosis and management of mild autonomous cortisol secretion.
Read more >>
Weitere Beiträge
GI and Hepatology
MAY
01
Transgender health care in the United States: legal, ethical and practical concerns for gastroenterologists in a changing landscape
By:
Sarah Singh
on
MAY
01
Nature Reviews Gastroenterology & Hepatology, Published online: 01 May 2024; doi:10.1038/s41575-024-00933-0Transgender and gender-diverse patients in the United States can have difficulty finding providers who are knowledgeable about their unique health-care needs. In many states, legislation limits the ability of physicians to provide gender-affirming and supportive care. Further awareness, advocacy and research is needed to help mitigate the discrimination and stigma endured by the transgender community.
Read more >>
APR
25
Pouchitis: pathophysiology and management
By:
Bo Shen
on
APR
25
Nature Reviews Gastroenterology & Hepatology, Published online: 25 April 2024; doi:10.1038/s41575-024-00920-5Pouchitis is a common condition that can occur after intestinal surgery. In this Review, Shen discusses our current understanding of the multifactorial pathophysiology, diagnosis and management of pouchitis, primarily in patients with underlying ulcerative colitis.
Read more >>
APR
23
Spatial genomics: mapping human steatotic liver disease
By:
Kylie P. Matchett
on
APR
23
Nature Reviews Gastroenterology & Hepatology, Published online: 23 April 2024; doi:10.1038/s41575-024-00915-2This Perspective discusses single-cell and single-nuclei RNA sequencing in metabolic dysfunction-associated steatotic liver disease and explains how our understanding of the pathology of the disease will accelerate following the advances in spatial transcriptomics.
Read more >>
APR
16
A crucial
Fusobacterium nucleatum
clade in colorectal cancer
By:
Katrina Ray
on
APR
16
Nature Reviews Gastroenterology & Hepatology, Published online: 16 April 2024; doi:10.1038/s41575-024-00930-3A crucial Fusobacterium nucleatum clade in colorectal cancer
Read more >>
APR
16
Artificial intelligence in liver cancer — new tools for research and patient management
By:
Julien Calderaro
on
APR
16
Nature Reviews Gastroenterology & Hepatology, Published online: 16 April 2024; doi:10.1038/s41575-024-00919-yArtificial intelligence (AI) is advancing rapidly and is already starting to transform cancer research and care. Here, the authors outline how AI could be incorporated into liver cancer management, highlighting areas with academic, commercial and clinical potential, as well as ongoing progress and pitfalls.
Read more >>
APR
05
Promoting allyship to support and uplift the LGBTQIA+ community
By:
Daniel J. Huynh
on
APR
05
Nature Reviews Gastroenterology & Hepatology, Published online: 05 April 2024; doi:10.1038/s41575-024-00928-xThe lesbian, gay, bisexual, transgender, queer, intersex and asexual (LGBTQIA+) community navigates a complex social landscape marked by strides in acceptance alongside enduring discrimination. Allies — individuals outside of the LGBTQIA+ spectrum who support and advocate for this community — are paramount, with allyship playing a critical part in influencing the health and well-being of LGBTQIA+ individuals.
Read more >>
APR
04
Publisher Correction: Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis
By:
María R. Aburto
on
APR
04
Nature Reviews Gastroenterology & Hepatology, Published online: 04 April 2024; doi:10.1038/s41575-024-00929-wPublisher Correction: Gastrointestinal and brain barriers: unlocking gates of communication across the microbiota–gut–brain axis
Read more >>
APR
04
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation
By:
Ipsita Mohanty
on
APR
04
Nature Reviews Gastroenterology & Hepatology, Published online: 04 April 2024; doi:10.1038/s41575-024-00914-3Bile acids have important roles in human metabolism and immune regulation. In this Perspective, Dorrestein and colleagues discuss the technologies and data science-related approaches that are improving our understanding of the diversity of bile acids and their multifaceted roles.
Read more >>
Weitere Beiträge
Nephrology
MAY
09
Podocyte-targeted therapies — progress and future directions
By:
Kristin Meliambro
on
MAY
09
Nature Reviews Nephrology, Published online: 09 May 2024; doi:10.1038/s41581-024-00843-zIn this Review, the authors summarize the mechanistic rationale for current treatments for podocytopathies and for novel podocyte-targeted therapies. They also discuss potential approaches to regenerate podocytes and to develop podocyte-specific drug delivery systems.
Read more >>
MAY
08
Spatial transcriptomics in health and disease
By:
Sanjay Jain
on
MAY
08
Nature Reviews Nephrology, Published online: 08 May 2024; doi:10.1038/s41581-024-00841-1Spatially resolved transcriptomic technologies enable the mapping of transcripts at single-cell or near single-cell resolution in a multiplex manner. This Review describes current and emerging spatial transcriptomic methods, their applications of relevance to kidney biology and remaining challenges for the field.
Read more >>
MAY
07
A patient perspective on kidney disease in the public health agenda
By:
Daniel Gallego
on
MAY
07
Nature Reviews Nephrology, Published online: 07 May 2024; doi:10.1038/s41581-024-00846-wChronic kidney disease is a life-changing diagnosis for millions of people worldwide, as the risk of disease progression and kidney failure creates unbearable uncertainty and limits lifestyle. The devastating impact of advanced kidney disease must be acknowledged in the public health agenda to pave way for improved outcomes for patients at all stages of disease.
Read more >>
APR
29
Role of the gut microbiota in the pathogenesis of IgA nephropathy
By:
Ellen F. Carney
on
APR
29
Nature Reviews Nephrology, Published online: 29 April 2024; doi:10.1038/s41581-024-00845-xRole of the gut microbiota in the pathogenesis of IgA nephropathy
Read more >>
APR
26
Progression and outcomes of rare kidney diseases
By:
Susan J. Allison
on
APR
26
Nature Reviews Nephrology, Published online: 26 April 2024; doi:10.1038/s41581-024-00844-yProgression and outcomes of rare kidney diseases
Read more >>
APR
26
Applications of SGLT2 inhibitors beyond glycaemic control
By:
Daniel V. O’Hara
on
APR
26
Nature Reviews Nephrology, Published online: 26 April 2024; doi:10.1038/s41581-024-00836-yHere, the authors discuss the beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors for a range of clinical outcomes beyond glucose lowering, including kidney and cardiovascular protection. They also discuss the need for implementation and adherence initiatives to help translate the benefits of these agents into real-world clinical outcomes.
Read more >>
APR
25
Post-translational modifications in kidney diseases and associated cardiovascular risk
By:
Heidi Noels
on
APR
25
Nature Reviews Nephrology, Published online: 25 April 2024; doi:10.1038/s41581-024-00837-xChronic kidney disease (CKD) is associated with several alterations in protein post-translational modifications. Here, the authors examine the evidence of these alterations, their links with CKD progression and cardiovascular risk in patients with CKD, and their potential clinical applications.
Read more >>
APR
24
Not every organ ticks the same
By:
Khaoula Talbi
on
APR
24
Nature Reviews Nephrology, Published online: 24 April 2024; doi:10.1038/s41581-024-00842-0A new study describes the development of proteomics-based ageing clocks that calculate the biological age of specific organs and define features of extreme ageing associated with age-related diseases. Their findings support the notion that plasma proteins can be used to monitor the ageing rates of specific organs and disease progression.
Read more >>
Weitere Beiträge
Neurology
MAY
09
The clinical importance of suspected non-Alzheimer disease pathophysiology
By:
Stephanie J. B. Vos
on
MAY
09
Nature Reviews Neurology, Published online: 09 May 2024; doi:10.1038/s41582-024-00962-ySuspected non-AD pathophysiology (SNAP) is a biomarker-based concept that describes individuals with normal amyloid and abnormal tau and/or neurodegeneration biomarker status. This Review discusses the origins of the SNAP construct, along with its prevalence, diagnostic and prognostic implications, and underlying neuropathology.
Read more >>
MAY
08
Artificial intelligence in epilepsy — applications and pathways to the clinic
By:
Alfredo Lucas
on
MAY
08
Nature Reviews Neurology, Published online: 08 May 2024; doi:10.1038/s41582-024-00965-9Integration of artificial intelligence into epilepsy management could revolutionize diagnosis and treatment. In this Review, the authors provide an overview of artificial intelligence applications that have been developed in epilepsy and discuss challenges that must be addressed to successfully integrate artificial intelligence into clinical practice.
Read more >>
APR
25
Author Correction: The complex aetiology of cerebral palsy
By:
Steven J. Korzeniewski
on
APR
25
Nature Reviews Neurology, Published online: 25 April 2024; doi:10.1038/s41582-024-00964-wAuthor Correction: The complex aetiology of cerebral palsy
Read more >>
APR
15
Neuronal activity drives glymphatic waste clearance
By:
Lisa Kiani
on
APR
15
Nature Reviews Neurology, Published online: 15 April 2024; doi:10.1038/s41582-024-00963-xTwo new studies show that clearance of waste, including pathogenic amyloid, through the glymphatic system is driven by synchronized neuronal activity.
Read more >>
APR
12
Addressing disparities in neurology by identifying gaps in hospital care
By:
Lisa Kiani
on
APR
12
Nature Reviews Neurology, Published online: 12 April 2024; doi:10.1038/s41582-024-00960-0Nature Reviews Neurology is interviewing individuals who are driving efforts to address disparities in neurology through a broad spectrum of diversity, equity and inclusion initiatives. We spoke with neurosurgeon Sonia Mejía Pérez from Mexico about her work to address gaps in hospital care for individuals from minority groups, such as LGBT+ people.
Read more >>
APR
12
Neurofilaments as biomarkers in neurological disorders — towards clinical application
By:
Michael Khalil
on
APR
12
Nature Reviews Neurology, Published online: 12 April 2024; doi:10.1038/s41582-024-00955-xNeurofilaments have been validated as specific body fluid biomarkers of neuro-axonal injury. In this Review, Khalil and colleagues provide an update on the structure and function of neurofilaments, analytical approaches and challenges in different clinical contexts, and progress towards clinical application of neurofilaments as a biomarker in various neurological disorders.
Read more >>
APR
10
BTK inhibitor falters in multiple sclerosis trials
By:
Heather Wood
on
APR
10
Nature Reviews Neurology, Published online: 10 April 2024; doi:10.1038/s41582-024-00958-8Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.
Read more >>
APR
10
EBV-specific T cells in multiple sclerosis
By:
Heather Wood
on
APR
10
Nature Reviews Neurology, Published online: 10 April 2024; doi:10.1038/s41582-024-00959-7New data recently reported at the ACTRIMS Forum add to growing evidence of an aetiological role for Epstein–Barr virus infection in multiple sclerosis.
Read more >>
Weitere Beiträge
Rheumatology
MAY
07
Bone-modifying drugs slow OA progression
By:
Sarah Onuora
on
MAY
07
Nature Reviews Rheumatology, Published online: 07 May 2024; doi:10.1038/s41584-024-01122-8Drugs used to treat osteoporosis could slow the progression of osteoarthritis, according to the findings of a study in mice.
Read more >>
MAY
03
Adropin inhibits fibrosis in SSc
By:
Robert Phillips
on
MAY
03
Nature Reviews Rheumatology, Published online: 03 May 2024; doi:10.1038/s41584-024-01121-9The peptide hormone adropin, which is downregulated in dermal fibroblasts in patients with systemic sclerosis (SSc), inhibits TGFβ-mediated fibrosis in in vitro and ex vivo models of human skin, and has potential for the treatment of SSc.
Read more >>
MAY
03
Rethinking antiphospholipid syndrome to guide future management and research
By:
Jason S. Knight
on
MAY
03
Nature Reviews Rheumatology, Published online: 03 May 2024; doi:10.1038/s41584-024-01110-yIn this Review, Knight and Erkan consider how the 2023 ACR–EULAR classification criteria for antiphospholipid syndrome (APS) can guide future research to subphenotype APS by understanding its pathophysiology, paving the way for the personalized and proactive management of individuals with APS.
Read more >>
MAY
02
Relapsing polychondritis: clinical updates and new differential diagnoses
By:
Philippe Mertz
on
MAY
02
Nature Reviews Rheumatology, Published online: 02 May 2024; doi:10.1038/s41584-024-01113-9Relapsing polychondritis, a rare inflammatory disorder that affects cartilaginous structures, presents challenges in diagnosis owing to overlapping symptoms with other conditions. This Review provides a clinical update on relapsing polychondritis, emphasizing the importance of distinguishing this disease from similar conditions.
Read more >>
APR
30
Granzyme serine proteases in inflammation and rheumatic diseases
By:
Alexandre Aubert
on
APR
30
Nature Reviews Rheumatology, Published online: 30 April 2024; doi:10.1038/s41584-024-01109-5Granzyme serine proteases are known for their perforin-dependent cytotoxic activities, but evidence also indicates that they have a range of non-cytotoxic, pro-inflammatory intracellular and extracellular functions. In this Review, the authors discuss granzyme biology with an emphasis on its involvement in rheumatic disease pathology.
Read more >>
APR
26
Treat-to-target or treat-to-dissolve strategy to improve gout treatment
By:
Pascal Richette
on
APR
26
Nature Reviews Rheumatology, Published online: 26 April 2024; doi:10.1038/s41584-024-01117-5Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.
Read more >>
APR
12
Advancing precision rheumatology through tissue and blood profiling
By:
George D. Kalliolias
on
APR
12
Nature Reviews Rheumatology, Published online: 12 April 2024; doi:10.1038/s41584-024-01115-7Multidimensional and single-cell profiling of peripheral blood and inflamed tissues is a powerful and high-resolution tool for the stratification of patients with autoimmune rheumatic diseases into distinct cellular and/or molecular endotypes. The road towards precision rheumatology is long, but the time has come to enter the territory of clinical validation.
Read more >>
APR
11
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis
By:
Virginia Byers Kraus
on
APR
11
Nature Reviews Rheumatology, Published online: 11 April 2024; doi:10.1038/s41584-024-01102-yEarly identification of osteoarthritis (OA) prior to the development of symptoms is challenging. Post-traumatic OA provides a model for the development of OA following a defined event. In this Review, the authors describe the existing knowledge relating to the biomarkers of post-traumatic OA, which might also be applicable to the identification of early non-traumatic OA.
Read more >>
Weitere Beiträge
Urology
MAY
08
We all get erections — de-gendering sexual arousal dysfunction in the ICD
By:
Lucy Greenwald
on
MAY
08
Nature Reviews Urology, Published online: 08 May 2024; doi:10.1038/s41585-024-00890-yDefinitions of sexual arousal dysfunction in the International Classification of Diseases use sex-specific binaries that omit the erectile basis of arousal in females. To provide equitable health care for all people with erectile dysfunction, these definitions must be de-gendered.
Read more >>
MAY
08
Centralization of care for rare genetic syndromes associated with cancer: improving outcomes and advancing research on VHL disease
By:
Alessandro Larcher
on
MAY
08
Nature Reviews Urology, Published online: 08 May 2024; doi:10.1038/s41585-024-00874-yIn this Perspective, Larcher et al. describe a dedicated treatment programme for Von Hippel–Lindau disease established at San Raffaele Hospital, which encompasses diagnosis, surveillance, treatment, research and outreach. The authors then discuss the benefits of care centralization for Von Hippel–Lindau disease and other rare diseases.
Read more >>
MAY
07
Asexuality: the invisible orientation
By:
Sarah Cosgriff
on
MAY
07
Nature Reviews Urology, Published online: 07 May 2024; doi:10.1038/s41585-024-00891-xAsexuality is often neglected in education and conversations around sexuality, making it essentially an ‘invisible orientation’. This lack of knowledge is associated with harmful misconceptions, which need challenging within the medical profession and in the general population to ensure inclusion of people who identify on the asexual spectrum.
Read more >>
MAY
07
Elevated periprostatic androgens, sneaky testosterone and its implications
By:
Masoud Bitaraf
on
MAY
07
Nature Reviews Urology, Published online: 07 May 2024; doi:10.1038/s41585-024-00878-8A subset of men with prostate cancer have elevated periprostatic androgens compared with levels in peripheral blood, which are associated with poor clinical outcomes after radical prostatectomy. This new paradigm for gonadal androgen physiology is termed ‘sneaky T’ phenomenon.
Read more >>
MAY
07
Current and emerging strategies to curb antibiotic-resistant urinary tract infections
By:
Aaron Simoni
on
MAY
07
Nature Reviews Urology, Published online: 07 May 2024; doi:10.1038/s41585-024-00877-9Antibiotic-resistant uropathogenic bacteria are becoming increasingly prevalent. In this Review, strategies for clinicians and researchers to address this challenge are delineated, including implementation of policies, stewardship practices, and the exploration of emerging therapeutic targets aimed at mitigating antibiotic resistance.
Read more >>
MAY
03
The evolving treatment landscape of metastatic urothelial cancer
By:
Giandomenico Roviello
on
MAY
03
Nature Reviews Urology, Published online: 03 May 2024; doi:10.1038/s41585-024-00872-0Urothelial cancer is the tenth most diagnosed cancer worldwide, and between 5% and 10% of patients have metastatic disease at diagnosis. Furthermore, up to 50% of patients are ineligible for cisplatin, the first-line treatment option, and require alternative options. In this comprehensive Review, the authors discuss the current and future therapeutic options for advanced urothelial cancer, including chemotherapeutics, targeted therapies and antibody–drug conjugates, and consider how these agents might change patient management.
Read more >>
MAY
02
Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma
By:
Chengheng Liao
on
MAY
02
Nature Reviews Urology, Published online: 02 May 2024; doi:10.1038/s41585-024-00876-wIn this Review, the authors discuss hypoxia signalling and therapeutic strategies targeting this pathway in renal cell carcinoma, with a specific focus on clear cell renal cell carcinoma, in which hypoxia signalling is primarily driven by Von Hippel–Lindau tumour suppressor (VHL) loss.
Read more >>
MAY
01
Strengthening preclinical testing to increase safety in surgical mesh
By:
Nicholas T. H. Farr
on
MAY
01
Nature Reviews Urology, Published online: 01 May 2024; doi:10.1038/s41585-024-00889-5Inflammatory and fibrotic responses to polypropylene mesh led to the withdrawal of this practice for treatment of stress urinary incontinence and pelvic organ prolapse in women in some countries. Improved material testing has been urged. We report poor responses of polypropylene mesh to repeated mechanical distension and macrophage interrogation. These results from preclinical in vitro testing show the potential of this approach for testing and improving materials before their introduction into the clinic.
Read more >>
Weitere Beiträge
Share
Tweet
Share
Mail
English version of this site is mostly translated automatically using "google translate". In case of language difficulties please do not hesitate to contact me.
Share by: